Moneyta · stock research · no sign-up needed
TMO
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q2 FY2026)
$12.0B
+15.7% y/y
Net income (Q2 FY2026)
$1.7B
as filed with the SEC
Institutions holding
2,629
+13 last quarter
Overview · Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and dis…
Management team
- Mr. Gianluca Pettiti · Executive VP and President of Life Science, Diagnostics & AppliedFind on LinkedIn
- Mr. Frederick M. Lowery · Executive VP and President of Laboratory Product & BioProductionFind on LinkedIn
- Mr. Michel Lagarde · Executive VP & COOFind on LinkedIn
- Mr. Stephen Williamson · Senior VP & CFOFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on TMO
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.